A Comparison of Patients on AVAMYS ® Versus NASONEX (A Trade Mark of Schering Corporation) and FLIXONASE ® on Key Health Outcome Measures

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

540 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-07-10

Study Completion Date

2009-08-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Previous publications have indicated that Allergic Rhinitis (AR) patients suffering from both ocular and nasal symptoms have a greater burden of illness and lower quality of life than patients suffering from nasal symptoms alone. Fluticasone furoate (FF) acts against both nasal and ocular symptoms. The purpose of this study was to evaluate the differences in symptom control (both perceptually and objectively) and resource use for patients with current seasonal AR.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Compare the Therapeutic Equivalence of Mometasone Furoate Nasal Spray, 50 mcg With Nasonex Nasal Spray in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis

NCT02125253

Seasonal Allergic Rhinitis

COMPLETED PHASE3

Intranasal Steroids and Oxymetazoline in Allergic Rhinitis

NCT00584987

Allergic Rhinitis

COMPLETED PHASE4

A Study Comparing Two Fluticasone Furoate Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis

NCT01279057

Rhinitis, Allergic, Seasonal

COMPLETED PHASE3

Mometasone Furoate Aqueous (MK-0887/SCH 032088) Nasal Spray vs Placebo and FLONASE® in Seasonal Allergic Rhinitis Patients (I94-001)

NCT03882047

Rhinitis, Allergic, Seasonal

COMPLETED PHASE3

Comparator Study Evaluating Patient Preference Of FFNS vs. FPNS

NCT00539006

Rhinitis, Allergic, Perennial

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

* Allergic rhinitis (AR) is a common inflammatory condition of the upper respiratory tract, nasal cavity and eyes affecting up to 20% of the population in the United States and Europe. The bothersome nature of AR symptoms can severely affect daily activities including ability to work and examination performance and impact on quality of life (QoL) and psychosocial well being.
* This study assesses the impact of Fluticasone furoate (FF) on the QoL of seasonal allergic rhinitis (SAR) patients, including the number of symptom-free days (SFD) and quality of life over the last 4 weeks, and compares this with other inhaled nasal steroids (INS): mometasone furate (MF) and fluticasone proprionate (FP).
* Selected physicians provide information including a range of demographic, symptom and treatment details for a number of their SAR patients. The patient themselves are then invited to provide details about their SAR including symptoms, the impact of AR upon their lifestyles, attitudes to treatment and completion of Health Related Quality of Life (HRQoL) instruments.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rhinitis, Allergic, Perennial

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

FF

Cohort of patients receiving fluticasome furoate

Fluticasone furoate

Intervention Type DRUG

cohort of patients receiving fluticasone furate

MF

cohort of patients on mometasone furoate

mometasone furoate

Intervention Type DRUG

cohort receiving mometasone furoate

FP

cohort of patients receiving fluticasone propionate

fluticasone propionate

Intervention Type DRUG

cohort of patients on fluticasone propionate

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Fluticasone furoate

cohort of patients receiving fluticasone furate

Intervention Type DRUG

mometasone furoate

cohort receiving mometasone furoate

Intervention Type DRUG

fluticasone propionate

cohort of patients on fluticasone propionate

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

AVAMYS™ NASONEX™ FLIXONASE™

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Current Seasonal Allergic Rhinitis sufferer (based on physician judgement)
* Currently receiving prescribed INS treatment (no other treatment restrictions apply)
* Have consumed at least one full prescription on the specified INS treatment
* No comorbid Asthma or COPD diagnosis
* Informed Consent